MedPath

Appili Therapeutics Inc.

Appili Therapeutics Inc. logo
πŸ‡¨πŸ‡¦Canada
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:2

Trial Phases

3 Phases

Phase 1:1
Phase 2:1
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)β€’ Click on a phase to view related trials

Phase 1
1 (33.3%)
Phase 2
1 (33.3%)
Phase 3
1 (33.3%)

The Prevent Severe COVID-19 (PRESECO) Study

Phase 3
Completed
Conditions
Covid19
Interventions
Drug: Placebo
First Posted Date
2020-10-23
Last Posted Date
2024-03-29
Lead Sponsor
Appili Therapeutics Inc.
Target Recruit Count
1187
Registration Number
NCT04600895
Locations
πŸ‡ΊπŸ‡Έ

Cahaba Research, Inc., Pelham, Alabama, United States

πŸ‡ΊπŸ‡Έ

Absolute Clinical Research, Phoenix, Arizona, United States

πŸ‡ΊπŸ‡Έ

B.G Clinical Research Center, LLC, Little Rock, Arkansas, United States

and more 34 locations

Control of COVID-19 Outbreaks in Long Term Care

Phase 2
Terminated
Conditions
COVID-19
SARS-CoV-2
Interventions
First Posted Date
2020-06-25
Last Posted Date
2023-02-21
Lead Sponsor
Appili Therapeutics Inc.
Target Recruit Count
67
Registration Number
NCT04448119
Locations
πŸ‡¨πŸ‡¦

Mount Sinai Hospital, Toronto, Ontario, Canada

Bioavailability of ATI-1501 With Taste Test Sub Study

Phase 1
Completed
Conditions
Bioequivalence
Interventions
First Posted Date
2017-11-08
Last Posted Date
2019-01-11
Lead Sponsor
Appili Therapeutics Inc.
Target Recruit Count
48
Registration Number
NCT03337126
Locations
πŸ‡¨πŸ‡¦

INC Research Inc., Toronto, Ontario, Canada

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.